Oliver Wyman March 23, 2023
Tobias Handschuh and Zoe Pillidge

Approvals for new therapies could be coming soon, changing the way we think about and treat dementia.

The research landscape is littered with failures in the search for treating Alzheimer’s disease. For decades, we’ve seen high-profile therapies advance in the clinical trial realm only to yield disappointing results in Phase 3 trials. But as populations age around the world and the costs of caring for Alzheimer’s patients grow, pharmaceutical companies and regulators must take notice of build off the momentum we are seeing with new therapies. They need to stay committed to research and development, as well as bolster an infrastructure that opens access to more patients.

Research showing that the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article